Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $15.6 million.

  • Sangamo Therapeutics' Accounts Payables fell 2139.86% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 2139.86%. This contributed to the annual value of $15.5 million for FY2024, which is 148.11% up from last year.
  • Latest data reveals that Sangamo Therapeutics reported Accounts Payables of $15.6 million as of Q3 2025, which was down 2139.86% from $10.7 million recorded in Q2 2025.
  • Sangamo Therapeutics' Accounts Payables' 5-year high stood at $22.4 million during Q4 2022, with a 5-year trough of $8.0 million in Q3 2021.
  • For the 5-year period, Sangamo Therapeutics' Accounts Payables averaged around $14.8 million, with its median value being $15.5 million (2023).
  • As far as peak fluctuations go, Sangamo Therapeutics' Accounts Payables tumbled by 5540.03% in 2021, and later skyrocketed by 12971.62% in 2022.
  • Over the past 5 years, Sangamo Therapeutics' Accounts Payables (Quarter) stood at $9.8 million in 2021, then surged by 129.72% to $22.4 million in 2022, then plummeted by 31.93% to $15.3 million in 2023, then rose by 1.48% to $15.5 million in 2024, then increased by 0.46% to $15.6 million in 2025.
  • Its last three reported values are $15.6 million in Q3 2025, $10.7 million for Q2 2025, and $18.2 million during Q1 2025.